Late Stage Chronic Kidney Disease Drugs Market is expected to reach US$ 11,096.9 Mn in 2027
Published Date : 16/09/2020

Report : Late Stage Chronic Kidney Disease Drugs Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others); Indication (Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalaemia); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and Geography

Calcimimetics Segment to Drive Growth of Late Stage Chronic Kidney Disease Drugs Market during 2020-2027

 

According to our new market research study titled” Late Stage Chronic Kidney Disease Drugs Market - Global Analysis and Forecast by Product Type, Indication and Distribution Channel” the global late stage chronic kidney disease drugs market is expected to reach US$ 11,096.9 million by 2027 from US$ 4,680.0 million in 2019; it is estimated to grow at a CAGR of 11.6% from 2020 to 2027. The report highlights the trends prevalent in the global late stage chronic kidney disease drugs market, and the drivers and deterrents pertaining to its growth.

 

Based on product type, the late stage chronic kidney disease drugs market is segmented into calcimimetics, vitamin D, potassium binders, calcium-based phosphate binders, and others. The calcimimetics segment held the highest share of the late stage chronic kidney disease drugs market in 2019 and is estimated to register the highest CAGR of 12.1% in the market during the forecast period. Factors such as high prevalence of hyperparathyroidism, increased research studies on calcimimetics are some of the impacting factors which drive the segment growth. For instance, in February 2017, Amgen received the US Food and Drug Administration (FDA) approval for Parsabiv, an etelcalcetide, for the treatment of secondary hyperparathyroidism (HPT) in adult patients with late stage chronic kidney disease receiving hemodialysis. Parsabiv is the first therapy approved for HPT in ESRD in 12 years. It is the only calcimimetic that is used for intravenous administration by the dialysis health care team thrice a week to the ending of the hemodialysis session.

 

The market growth is also attributed to a few key factors such as high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.

 

AbbVie Inc.; Amgen; AstraZeneca; Sanofi; Kyowa Kirin Co., Ltd.; Takeda Pharmaceutical Company Limited; Astellas Pharma Inc.; Bayer AG; Vifor Pharma Management Ltd.; and Akebia Drugs, Inc. are among the prominent players operating in the late stage chronic kidney disease drugs market. The market players are focused on organic strategies to sustain their position in the market. For instance, in Jul-2020, Bayer announced positive results from the Phase III FIDELIO-DKD study, assessing the efficacy and safety of finerenone versus placebo when added to standard of care for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D), has met its primary endpoint.

Global Late Stage Chronic Kidney Disease Drugs Market, By Region, 2019 (%)

Global Late Stage Chronic Kidney Disease Drugs Market, By Region, 2019 (%)

The Report Segments the Global Late Stage Chronic Kidney Disease Drugs Market as Follows:

 

By Product Type

  • Calcimimetics
  • Vitamin D
  • Sterols
  • Potassium Binders
  • Calcium-Based Phosphate Binders

By Indication

  • Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
  • Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
  • Late Stage Chronic Kidney Disease Induced Hyperkalaemia

By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Geography

  • North America
      • US
      • Canada
      • Mexico
  • Europe
      • UK
      • Germany
      • France
      • Italy
      • Spain
  • Asia Pacific (APAC)
      • Japan
      • China
      • India
      • Australia
      • South Korea
  • Middle East and Africa (MEA)
      • South Africa
      • UAE
      • Saudi Arabia
  • South and Central America (SCAM)
      • Brazil
      • Argentina

 

Contact Us
Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com
DOWNLOAD PDF BROCHURE